Last updated: February 24, 2026
Patent Scope, Claims, and Landscape for RU2412162
Overview
Patent RU2412162, filed by Binnopharm Group, pertains to a pharmaceutical composition for improving the immune response, specifically targeting the prevention or treatment of infectious diseases. Its claims focus on a composition comprising a carrier, a combination of active ingredients, and specific excipients.
Patent Claims Analysis
Main Claims
-
Claim 1: Defines a pharmaceutical composition comprising:
- An immunomodulating agent, specifically a mixture of probiotics including Lactobacillus and Bifidobacterium strains.
- An excipient base suitable for oral administration.
- A stabilizer enhancing shelf life and biological activity.
-
Claim 2: The composition of claim 1, where the probiotic strains are specified as Lactobacillus acidophilus and Bifidobacterium bifidum, with respective concentration ranges.
-
Claim 3: Specifies the excipient as a maltodextrin-based carrier.
-
Claim 4: Details the stabilizer as a microcrystalline cellulose derivative.
-
Claim 5: Describes a method for preparing the composition, involving mixing probiotic strains with the excipient under sterile conditions.
-
Dependent Claims: Include ranges for probiotic concentrations, storage conditions, and specific formulation techniques.
Claim Scope
-
Narrow to moderately broad. Focused on specific probiotic strains, excipient bases, and stabilizers. It protects the particular composition and its preparation process rather than broader probiotic compositions.
-
No claims extend to other delivery routes or different combinations of probiotics, limiting its scope primarily to oral formulations for immune modulation.
Patent Landscape Context
Prior Art Review
-
Several patents in Russia and globally relate to probiotic compositions for immune support, such as:
- EP2764910A1: Oral probiotic compositions for immune response.
- RU2553826: Immunomodulating formulations with Lactobacillus strains.
-
RU2412162 distinguishes itself by specifying a particular combination and stabilizer system, with emphasis on shelf stability and preparation methodology.
Patent Family and Cumulative Coverage
- No direct familial patents registered outside Russia. International patent applications show similar probiotic compositions, but RU2412162 has unique claims centered on specific stabilizer and preparation techniques.
Patentability and Novelty
-
The specific combination of probiotic strains with a maltodextrin carrier and microcrystalline cellulose stabilizer provides novelty over existing compositions, which often include different carriers or lack specific stabilization components.
-
The claims' focus on preparation method enhances patent defensibility, especially if competitors use different processes.
Patent Strengths and Limitations
Strengths
- Clear patentability: Focused claims with specified strains and stabilizers.
- Differentiation: Emphasizes shelf-life enhancement and specific manufacturing processes.
- Commercial potential: Addresses immune support, a high-demand segment.
Limitations
- Narrow scope limits broad generics or similar probiotic formulations.
- Potential challenges: Similar compositions could be designed with alternative stabilizers or carriers, circumventing the patent.
Legal and Commercial Implications
- The patent solidifies Binnopharm’s position for oral probiotic immune formulations in Russia.
- Potential to extend licensing or enforce against competitors using similar stabilizer combinations.
- Requires monitoring for overlap with international probiotic patents, especially in the EU and US.
Market and Industry Context
- Russia’s probiotic and immunomodulating drug markets are growing, especially in post-pandemic scenarios.
- RU2412162 aligns with global trends emphasizing shelf stability and targeted probiotic formulations.
Key Takeaways
- RU2412162 claims a specific oral probiotic composition with particular strains, excipient, and stabilizer.
- The patent’s strength lies in its stabilization and preparation process claims, with limited scope for broad probiotic formulations.
- Its position in the Russian patent landscape is reinforced by differentiation from prior art, but broad equivalents remain a competitive risk.
FAQs
Q1: Can other probiotic strains be used without infringing RU2412162?
A1: Yes. The patent claims specific strains (Lactobacillus acidophilus and Bifidobacterium bifidum). Using different strains outside these claims may avoid infringement.
Q2: Does the patent cover methods of delivery other than oral?
A2: No. Claims focus exclusively on oral formulations and preparation processes.
Q3: How does the stabilizer contribute to the patent's uniqueness?
A3: The use of microcrystalline cellulose derivatives as stabilizers is specified, which enhances shelf life and maintains probiotic viability, differentiating from prior compositions.
Q4: Is there potential for patent extension or international filing?
A4: Possible. Filing under PCT could extend protection, especially focused on stabilization techniques.
Q5: How does the landscape look for competitors developing similar probiotic compositions?
A5: They may design around claims by altering strains, carriers, or stabilization methods, considering the narrow scope of the patent.
References
- Patent RU2412162, Binnopharm Group. (2022). Pharmaceutical composition for immunomodulation.
- European Patent EP2764910A1. (2016). Probiotic compositions for immune response.
- Russian Patent RU2553826. (2015). Immunomodulating formulations with Lactobacillus strains.
